Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical has announced that its self-developed Envonalkib Citrate Capsules, a novel drug for treating ALK-positive non-small cell lung cancer, has been approved for marketing in China. Envonalkib has shown superiority over Crizotinib in clinical trials, significantly improving median progression-free survival and offering notable benefits for patients with brain metastases. This approval marks a significant advancement in the company’s lung cancer drug portfolio.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
